CA2865810C - Treatment of mucositis with immunoglobulin - Google Patents

Treatment of mucositis with immunoglobulin Download PDF

Info

Publication number
CA2865810C
CA2865810C CA2865810A CA2865810A CA2865810C CA 2865810 C CA2865810 C CA 2865810C CA 2865810 A CA2865810 A CA 2865810A CA 2865810 A CA2865810 A CA 2865810A CA 2865810 C CA2865810 C CA 2865810C
Authority
CA
Canada
Prior art keywords
composition
mucositis
iga
immunoglobulin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2865810A
Other languages
English (en)
French (fr)
Other versions
CA2865810A1 (en
Inventor
Christoph Aebi
Sonja Christina Lueer
Alexander Schaub
Sylvia Miescher
Adrian Zuercher
Cedric Pierre Vonarburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bern
CSL Behring AG
Original Assignee
University of Bern
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bern, CSL Behring AG filed Critical University of Bern
Publication of CA2865810A1 publication Critical patent/CA2865810A1/en
Application granted granted Critical
Publication of CA2865810C publication Critical patent/CA2865810C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2865810A 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin Active CA2865810C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12158939.4A EP2636683A1 (en) 2012-03-09 2012-03-09 Treatment of mucositis with Immunoglobulin
EP12158939.4 2012-03-09
PCT/EP2013/054722 WO2013132063A1 (en) 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin

Publications (2)

Publication Number Publication Date
CA2865810A1 CA2865810A1 (en) 2013-09-12
CA2865810C true CA2865810C (en) 2022-09-06

Family

ID=45808320

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865810A Active CA2865810C (en) 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin

Country Status (10)

Country Link
US (1) US9546209B2 (enExample)
EP (2) EP2636683A1 (enExample)
JP (1) JP6238910B2 (enExample)
KR (1) KR102120620B1 (enExample)
CN (1) CN104254543B (enExample)
AU (1) AU2013201394B2 (enExample)
CA (1) CA2865810C (enExample)
DK (1) DK2822966T3 (enExample)
ES (1) ES2660157T3 (enExample)
WO (1) WO2013132063A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
CN104254542A (zh) 2012-03-09 2014-12-31 瑞士杰特贝林生物制品有限公司 包含分泌-样免疫球蛋白的组合物
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
AU2017357044B2 (en) 2016-11-10 2024-01-04 Becton, Dickinson And Company Timeline system for monitoring a culture media protocol
JP2026502571A (ja) * 2023-01-13 2026-01-23 マイケル アール． サイモン 壊死性腸炎を治療するための分泌型ＩｇＡおよび分泌型ＩｇＭの調製方法およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Also Published As

Publication number Publication date
US9546209B2 (en) 2017-01-17
CA2865810A1 (en) 2013-09-12
EP2822966B1 (en) 2017-11-29
KR102120620B1 (ko) 2020-06-10
CN104254543B (zh) 2018-06-05
JP6238910B2 (ja) 2017-11-29
AU2013201394B2 (en) 2015-09-03
JP2015513554A (ja) 2015-05-14
DK2822966T3 (en) 2018-02-26
CN104254543A (zh) 2014-12-31
KR20140145587A (ko) 2014-12-23
US20150030613A1 (en) 2015-01-29
EP2636683A1 (en) 2013-09-11
EP2822966A1 (en) 2015-01-14
WO2013132063A1 (en) 2013-09-12
ES2660157T3 (es) 2018-03-21
AU2013201394A1 (en) 2013-09-26
HK1204629A1 (en) 2015-11-27

Similar Documents

Publication Publication Date Title
EP3157565B1 (en) Treatment of polybacterials infections
US10221233B2 (en) Compositions comprising secretory-like immunoglobulins
US20240016931A1 (en) Anti-tslp antibody pharmaceutical composition and use thereof
AU2011268229B2 (en) Arthritis treatment
EP2822966B1 (en) Treatment of mucositis with immunoglobulin a
AU2012236106A1 (en) Treatment for dermatological pathologies
JP2025165988A (ja) プラスミノーゲンとの結合のための抗体
US12358977B2 (en) Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the IL-20R
HK1204629B (en) Treatment of mucositis with immunoglobulin a
WO2014160098A2 (en) Bordetella specific human recombinant antibodies and uses thereof
KR102241619B1 (ko) 병원체의 면역 억제 기능을 저해하는 모노클로날 항체, 그의 항원 결합 단편 및 이러한 항체를 생성하는 하이브리도마
TW202434625A (zh) Lag-3及pd-1/lag-3抗體
TWI665215B (zh) 具有抑制致病原的免疫抑制功能的單株抗體，其抗原結合片段，以及產生該等抗體的融合瘤
JP2021530237A5 (enExample)
AU2015258242A1 (en) Compositions
HK1236126B (en) Treatment of polybacterials infections
HK1236126A1 (en) Treatment of polybacterials infections
WO2016102641A1 (en) Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190304

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241212

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260210